ANN ARBOR, Mich., Dec. 11, 2013 /PRNewswire/ -- IROA® is a novel metabolite labeling tool which enables the next-generation metabolomics IROA ClusterFinder™ data analysis software to eliminate artifacts, and find, identify and quantitate biochemical compounds of interest. IROA Biochemical Quantitation Series 100 and 200 kits make it easy for researchers to analyze biochemicals in bacteria and yeast when combined with sample preparation and mass spectrometry. Designed to quantitate metabolic differences between two groups of cell populations, the kits include uniquely stably-labeled carbon sources provided with either YNB or Minimal media.
Instead of using 99% 13C-label, in an IROA protocol the control and experimental samples are isotopically labeled with 95 and 5% 13C (respectively), and the two sample populations are mixed together for uniform extraction, sample preparation, and LC-MS analysis. This labeling strategy provides several advantages over conventional approaches: 1) compounds arising from biosynthesis (experimental and control) have a unique isotopic signature and all unsigned artifactual signals can be removed from the dataset (usually the largest portion of the dataset); 2) sample-to-sample variance from sample extraction and preparation is minimized because the control and experiment are combined into a single sample; 3) measurement of both the molecular weight and the exact number of carbon atoms in each molecule provides extremely accurate molecular formulas; and 4) as the protocol uses a central biochemical point of reference embedded in every sample, relative concentrations of all metabolites are easily determined.
The IROA Biochemical Quantitation Series 100 and 200 kits provide access to ClusterFinder™ and the IROA® Portal providing an affordable, fast solution for the complete interpretation of an experimental dataset. IROA Technologies is offering an introductory 20% discount offer – please use coupon 'DiscDec2013'. http://www.iroatech.com/
Felice De Jong
|SOURCE IROA Technologies|
Copyright©2012 PR Newswire.
All rights reserved